Source: Mesoblast Limited
Date: May 2, 2007
Summary:
Australia's adult stem cell company, Mesoblast Limited today announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks.
